USA - engelsk - NLM (National Library of Medicine)

ucb, inc. - certolizumab pegol (unii: umd07x179e) (certolizumab pegol - unii:umd07x179e) - certolizumab pegol 200 mg in 1 ml - cimzia is indicated for reducing signs and symptoms of crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (ra). cimzia is indicated for the treatment of adult patients with active psoriatic arthritis (psa). cimzia is indicated for the treatment of adults with active ankylosing spondylitis (as). [see clinical studies (14.4)] cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation [see clinical studies (14.5)]. cimzia is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy [see clinical studies (14.6)] cimzia is con

Den europeiske union - rumensk - EMA (European Medicines Agency)

ucb pharma sa  - certolizumab pegol - artrita, reumatoida - imunosupresoare - poliartrita arthritiscimzia, în asociere cu metotrexat (mtx), este indicat pentru:tratamentul moderată până la severă, cu artrită reumatoidă activă (pr) la pacienții adulți, atunci când răspunsul la medicamente antireumatice modificatoare ale bolii (marmb), inclusiv mtx, a fost inadecvat. cimzia poate fi administrat în monoterapie în caz de intoleranță la mtx sau atunci când continuarea tratamentului cu mtx este inappropriatethe tratament de active, severe și progresive, la ra la adulți nu au fost tratați anterior cu mtx sau alte dmard.. cimzia a fost demonstrat de a reduce rata progresiei distrucției articulare de raze x și de a îmbunătăți funcția fizică, atunci când este administrată în combinație cu mtx. spondilartrita axială cimzia este indicat pentru tratamentul pacienților adulți cu active severe, spondilartrita axială, care cuprinde:spondilita anchilozantă (sa)adulți cu spondilită anchilozantă activă severă care au avut un răspuns inadecvat sau intoleranță la antiinflamatoarele nesteroidiene (ains). sp

Den europeiske union - rumensk - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohn boala - imunosupresoare - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia poate fi administrat în monoterapie în caz de intoleranță la metotrexat sau atunci când tratamentul continuu cu metotrexat este inadecvat. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards.,psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (nsaid).,non-radiographic axial spondyloarthritis cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation as indicated by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (nsaids).,plaque psoriasis cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards. psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (nsaid).,non-radiographic axial spondyloarthritis cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation as indicated by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (nsaids).,plaque psoriasis cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Israel - engelsk - Ministry of Health

neopharm ltd, israel - certolizumab pegol - solution for injection - certolizumab pegol 200 mg/ml - certolizumab pegol - rheumatoid arthritis:cimzia, in combination with methotrexate (mtx), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate, has been inadequate. cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritis:cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: ankylosing spondylitis (as): adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). axial spondyloarthritis without radiographic evidence of as adults with severe active axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri), who have had an inadequate response to, or are intolerant to nsaids. crohn's disease :cimzia is indicated for reducing signs and symptoms of crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.plaque psoriasis:cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.

Chile - spansk - ISPC (Instituto de Salud Pública de Chile)

laboratorios biopas s.a. - certolizumab - sin formulas

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - certolizumabum pegolum - injizierbare lösung - certolizumabum pegolum 200 mg, natrii acetas, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.257 mg. tela cum: alcohol isopropylicus. - morbus crohn, rheumatoider arthritis, psoriasis-arthritis, - röntgenologischer axialer spondyloarthritis, einschließlich spondyloarthrite spondylitis und axiale spondyloarthritis ohne radiologische zeichen, plaque-psoriasis bei erwachsenen - biotechnologika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - certolizumabum pegolum - injektionslösung in einem fertigpen - certolizumabum pegolum 200 mg, natrii acetas, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.257 mg. tela cum: alcohol isopropylicus. - morbus crohn, rheumatoider arthritis, psoriasis-arthritis, - röntgenologischer axialer spondyloarthritis, einschließlich spondyloarthrite spondylitis und axiale spondyloarthritis ohne radiologische zeichen, plaque-psoriasis bei erwachsenen - biotechnologika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - certolizumabum pegolum - soluzione iniettabile - certolizumabum pegolum 200 mg, natrii acetas, natrii chloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.257 mg. tela cum: alcohol isopropylicus. - morbo di crohn, l'artrite reumatoide, l'artrite psoriasica, spondyloarthrite assiale, che spondyloarthrite e spondilite spondyloarthrite assiale senza segni radiografici, psoriasi a placche in adulti - biotechnologika